Table 2.
Results of meta-analysis for cyp2c19*2 Polymorphism and Clopidogrel resistance.
| Genetic models | Subgroup | n | OR | 95%CI | P | I2 (%) | P for heterogeneity | Model | P for Publication bias |
|---|---|---|---|---|---|---|---|---|---|
| Allelic model (A vs. G) | Overall | 12 | 2.42 | 1.97–2.98 | 0.000 | 64.8 | 0.001 | REM | 0.125 |
| Caucasian | Asian | 10 | 2.37 | 1.86–3.02 | 0.000 | 69.3 | 0.001 | REM | 0.178 |
| Caucasian | 2 | 2.77 | 2.03–3.79 | 0.000 | 0.0 | 0.731 | FEM | NA | |
| Year | ≤ 2013 | 5 | 1.96 | 1.68–2.30 | 0.000 | 7.2 | 0.366 | FEM | 0.223 |
| >2013 | 7 | 2.88 | 2.07–3.99 | 0.000 | 65.1 | 0.000 | REM | 0.795 | |
| Definition of clopidogrel resistance | Percent inhibition of ADP ≤ 10% | 2 | 1.98 | 1.53–2.57 | 0.000 | 32.4 | 0.224 | REM | NA |
| ADP-induced MPA > 50% | 3 | 2.22 | 1.47–3.36 | 0.000 | 69.3 | 0.038 | REM | 0.363 | |
| Others | 7 | 2.76 | 2.00–3.80 | 0.000 | 64.0 | 0.011 | REM | 0.766 | |
| Dominant model (AA + AG vs. GG) | Overall | 12 | 2.74 | 2.09–3.59 | 0.000 | 63.0 | 0.002 | REM | 0.063 |
| Caucasian | Asian | 10 | 2.74 | 1.97–3.80 | 0.000 | 68.0 | 0.001 | REM | 0.093 |
| Caucasian | 2 | 2.90 | 2.02–4.16 | 0.000 | 0.0 | 0.334 | FEM | NA | |
| Year | ≤ 2013 | 5 | 2.12 | 1.74–2.59 | 0.000 | 0.0 | 0.760 | FEM | 0.116 |
| >2013 | 7 | 3.49 | 2.15–5.69 | 0.000 | 70.3 | 0.003 | REM | 0.361 | |
| Definition of clopidogrel resistance | Percent inhibition of ADP ≤ 10% | 2 | 2.19 | 1.64–2.93 | 0.000 | 0.0 | 0.516 | FEM | NA |
| ADP-induced MPA > 50% | 3 | 2.81 | 1.44–5.50 | 0.002 | 76.8 | 0.013 | REM | 0.296 | |
| Others | 7 | 3.03 | 1.96–4.68 | 0.000 | 66.6 | 0.006 | REM | 0.361 | |
| Recessive model (AA vs. AG + GG) | Overall | 12 | 4.07 | 3.06–5.41 | 0.000 | 0.0 | 0.595 | FEM | 0.017 |
| Caucasian | Asian | 10 | 3.98 | 2.95–5.37 | 0.000 | 0.0 | 0.484 | FEM | 0.031 |
| Caucasian | 2 | 4.96 | 1.99–12.36 | 0.001 | 0.0 | 0.411 | FEM | NA | |
| Year | ≤ 2013 | 5 | 3.25 | 2.31–4.59 | 0.000 | 0.0 | 0.721 | FEM | 0.306 |
| >2013 | 7 | 6.52 | 3.86–11.01 | 0.000 | 0.0 | 0.856 | FEM | 0.778 | |
| Definition of clopidogrel resistance | Percent inhibition of ADP ≤ 10% | 2 | 3.34 | 2.07–5.38 | 0.000 | 0.0 | 0.578 | FEM | NA |
| ADP-induced MPA > 50% | 3 | 3.25 | 2.00–5.29 | 0.000 | 4.0 | 0.353 | FEM | 0.386 | |
| Others | 7 | 6.53 | 3.81–11.17 | 0.000 | 0.0 | 0.855 | FEM | 0.740 | |
| Homozygous model(AA vs. GG) | Overall | 12 | 5.70 | 4.22–7.71 | 0.000 | 33.9 | 0.119 | FEM | 0.085 |
| Caucasian | Asian | 10 | 5.62 | 4.09–7.73 | 0.000 | 44.7 | 0.062 | FEM | 0.097 |
| Caucasian | 2 | 6.38 | 2.51–16.22 | 0.000 | 0.0 | 0.544 | FEM | NA | |
| Year | ≤ 2013 | 5 | 4.31 | 2.99–6.21 | 0.000 | 0.0 | 0.734 | FEM | 0.320 |
| >2013 | 7 | 10.52 | 6.01–18.41 | 0.000 | 15.7 | 0.310 | FEM | 0.832 | |
| Definition of clopidogrel resistance | Percent inhibition of ADP ≤ 10% | 2 | 4.58 | 2.74–7.64 | 0.000 | 0.0 | 0.572 | FEM | NA |
| ADP-induced MPA > 50% | 3 | 4.62 | 2.79–7.67 | 0.000 | 63.1 | 0.067 | REM | 0.392 | |
| Others | 7 | 9.18 | 5.18–16.26 | 0.000 | 4.5 | 0.393 | FEM | 0.854 | |
| Heterozygous model (AG vs. GG) | Overall | 12 | 2.32 | 1.76–3.07 | 0.000 | 61.4 | 0.003 | REM | 0.085 |
| Caucasian | Asian | 10 | 2.29 | 1.65–3.18 | 0.000 | 65.2 | 0.002 | REM | 0.113 |
| Caucasian | 2 | 2.56 | 1.55–4.22 | 0.000 | 42.1 | 0.189 | FEM | NA | |
| Year | ≤ 2013 | 5 | 1.82 | 1.48–2.25 | 0.000 | 0.0 | 0.897 | FEM | 0.095 |
| >2013 | 7 | 2.91 | 1.75–4.85 | 0.000 | 70.4 | 0.002 | REM | 0.443 | |
| Definition of clopidogrel resistance | Percent inhibition of ADP ≤ 10% | 2 | 1.88 | 1.38–2.55 | 0.000 | 0.0 | 0.947 | FEM | NA |
| ADP-induced MPA > 50% | 3 | 2.41 | 1.27–4.57 | 0.007 | 72.5 | 0.026 | REM | 0.294 | |
| Others | 7 | 2.52 | 1.58–4.03 | 0.000 | 68.2 | 0.004 | REM | 0.439 |
OR, odds ratio; FEM, fixed-effects model; REM, random-effects model.